9 results on '"Kronbichler, Andreas"'
Search Results
2. Diagnosis and management of ANCA-associated vasculitis.
- Author
-
Kronbichler, Andreas, Bajema, Ingeborg M, Bruchfeld, Annette, Mastroianni Kirsztajn, Gianna, and Stone, John H
- Subjects
- *
MICROSCOPIC polyangiitis , *ANTINEUTROPHIL cytoplasmic antibodies , *VASCULITIS , *DIAGNOSIS , *DISEASE remission , *MULTINUCLEATED giant cells , *GRANULOMATOSIS with polyangiitis - Abstract
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis consists of two main diseases, granulomatosis with polyangiitis and microscopic polyangiitis, and remains among the most devastating and potentially lethal forms of autoimmune inflammatory disease. Granulomatosis with polyangiitis and microscopic polyangiitis are characterised by a necrotising vasculitis that can involve almost any organ, and have generally been studied together. The diseases commonly affect the kidneys, lungs, upper respiratory tract, skin, eyes, and peripheral nerves. Granulomatous inflammation and multinucleated giant cells are key pathological hallmarks of granulomatosis with polyangiitis, but are absent in microscopic polyangiitis. Many immune system events are essential to disease aetiopathogenesis, such as activation of the alternative complement pathway, neutrophil activation via complement receptors, and the influx of inflammatory cells, including monocytes and macrophages. These cells perpetuate inflammation and lead to organ damage. During the 21st century, the management of ANCA-associated vasculitis has moved away from reliance on cytotoxic medications and towards targeted biological medications for both the induction and maintenance of disease remission. Earlier diagnosis, partly the result of more reliable ANCA testing, has led to improved patient outcomes and better survival. Reductions in acute disease-related mortality have now shifted focus to long-term morbidities related to ANCA-associated vasculitis and their treatments, such as chronic kidney disease and cardiovascular disease. Therapeutic approaches in both clinical trials and clinical practice still remain too reliant on glucocorticoids, and continued efforts to reduce toxicity from glucocorticoids remain a priority in the development of new treatment strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Management of antineutrophil cytoplasmic antibody–associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recommendations.
- Author
-
Moura, Marta Casal, Gauckler, Philipp, Anders, Hans-Joachim, Bruchfeld, Annette, Fernandez-Juarez, Gema M, Floege, Jürgen, Frangou, Eleni, Goumenos, Dimitrios, Segelmark, Marten, Turkmen, Kultigin, Kooten, Cees van, Tesar, Vladimir, Geetha, Duvuru, Fervenza, Fernando C, Jayne, David R W, Stevens, Kate I, and Kronbichler, Andreas
- Subjects
CHURG-Strauss syndrome ,MICROSCOPIC polyangiitis ,GRANULOMATOSIS with polyangiitis ,VASCULITIS ,GLOMERULONEPHRITIS ,NEPHRITIS ,KIDNEY failure - Abstract
Updated guidelines on the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) were released in 2021 by the American College of Rheumatology jointly with the Vasculitis Foundation and, subsequently, in 2022 by the European Alliance of Associations for Rheumatology. In addition, in 2021, the Kidney Disease: Improving Global Outcomes had released updated recommendations on the treatment of AAV with glomerulonephritis (AAV-GN). Kidney involvement is particularly relevant in microscopic polyangiitis and granulomatosis with polyangiitis, but is less frequent in eosinophilic granulomatosis with polyangiitis. The management of AAV-GN has been a focus for drug development and change over the past 10 years. Avoidance of progression to end-stage kidney disease (ESKD) or kidney failure is one of the main unmet needs in the management of AAV, with ESKD having a major impact on morbidity, health costs and mortality risk. Relevant changes in AAV-GN management are related to remission-induction treatment of patients with severe kidney disease, the use of glucocorticoids and avacopan, and remission-maintenance treatment. All the documents provide guidance in accordance with the evidence-based standard of care available at the time of their release. With our work we aim to (i) show the progress made and identify the differences between guidelines and recommendations, (ii) discuss the supporting rationale for those, and (iii) identify gaps in knowledge that could benefit from additional research and should be revised in subsequent updates. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Avacopan for ANCA-associated vasculitis – information for prescribers.
- Author
-
McGovern, Dominic, Jones, Rachel B, Willcocks, Lisa C, Smith, Rona M, Jayne, David R W, and Kronbichler, Andreas
- Subjects
VASCULITIS ,MICROSCOPIC polyangiitis - Abstract
The approval of avacopan as a treatment for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) by the US Food and Drug Administration (FDA) in 2021 and the European Medicines Agency (EMA) in 2022 represents an important therapeutic advance. Of the patients receiving avacopan, 13.3% suffered serious infections versus 15.2% in those in the prednisone group, and serious opportunistic infections were less common in patients receiving avacopan (3.6% in the avacopan group, 6.7% in the prednisone group) [[10]]. Insights from the ADVOCATE study: respiratory tract involvement in patients with ANCA-associated vasculitis in a randomized, double-blind, placebo-controlled, phase 3 trial of avacopan. Recovery of renal function among ANCA-associated vasculitis patients with baseline eGFR <=20 in the avacopan ADVOCATE trial. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
5. Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis.
- Author
-
Berti, Alvise, Alsawas, Mouaz, Jawaid, Tabinda, Prokop, Larry J, Lee, Jiwon M, Jeong, Gwang Hun, Quintana, Luis F, Moiseev, Sergey, Vaglio, Augusto, Tesar, Vladimir, Geetha, Duvuru, Shin, Jae I l, and Kronbichler, Andreas
- Subjects
MYCOPHENOLIC acid ,REMISSION induction ,MICROSCOPIC polyangiitis ,CLINICAL trials ,VASCULITIS ,DISEASE remission - Abstract
Background Uncertainties exist about the use of mycophenolate mofetil (MMF) in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitis (AAV), particularly for remission maintenance. Methods Systematic review and meta-analysis of phase II and III trials assessing the use of MMF in AAV, granulomatosis with polyangiitis and microscopic polyangiitis (MPA). A comprehensive search of several databases (Medline, EMBASE, Cochrane, Web of Science, Scopus) from inception to 5 May 2020 has been conducted. Trial data were extracted to estimate odds ratios (ORs) and estimates (ES) for MMF efficacy (remission-induction and maintenance). Severe adverse effects (SAEs) were collected. Results From 565 articles captured, 10 met the predefined criteria, 5 phase II and 5 III trials; 4 assessed remission-induction, 3 remission maintenance and 3 both. The pooled OR for remission-induction at 6 months was 1.06 (95% confidence interval 0.74, 1.52), with no significant difference by subgroup meta-analysis of trials stratified by different study-level features (i.e. kidney disease, MPA, myeloperoxidase-ANCA positivity, newly diagnosed disease) (P > 0.05). The overall ES for remission maintenance at the end of follow-up ranged between 51% and 91% (I
2 = 74.8%). Subgroup meta-analysis identified kidney involvement as a possible source of heterogeneity, yielding a significantly higher rate of sustained remission in trials enrolling only patients with kidney involvement (92%, 76–100%) versus those enrolling patients with and without kidney involvement (56%, 45–66%). Results were similar in multiple sensitivity analyses. During follow-up, the frequency of SAEs in MMF-based treatment arms was 31.8%. Conclusions In AAV, MMF use was significantly associated with higher sustained remission rates in trials enrolling only patients with kidney involvement. These findings might influence clinical practice. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
6. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis.
- Author
-
Suppiah, Ravi, Robson, Joanna C., Grayson, Peter C., Ponte, Cristina, Craven, Anthea, Khalid, Sara, Judge, Andrew, Hutchings, Andrew, Merkel, Peter A., Luqmani, Raashid A., Watts, Richard A., Gatenby, Paul, Hill, Catherine, Ranganathan, Dwarakanathan, Kronbichler, Andreas, Blockmans, Daniel, Barra, Lillian, Carette, Simon, Pagnoux, Christian, and Dhindsa, Navjot
- Subjects
COMMITTEES ,CONFIDENCE intervals ,RHEUMATOLOGY ,ANTINEUTROPHIL cytoplasmic antibodies ,INTERSTITIAL lung diseases ,DESCRIPTIVE statistics ,LOGISTIC regression analysis ,GLOMERULONEPHRITIS ,ERYTHROCYTES ,MICROSCOPIC polyangiitis ,LONGITUDINAL method ,VASCULITIS - Abstract
Objective: To develop and validate classification criteria for microscopic polyangiitis (MPA). Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in 5 phases: 1) identification of candidate items using consensus methodology, 2) prospective collection of candidate items present at the time of diagnosis, 3) data‐driven reduction of the number of candidate items, 4) expert panel review of cases to define the reference diagnosis, and 5) derivation of a points‐based risk score for disease classification in a development set using least absolute shrinkage and selection operator logistic regression, with subsequent validation of performance characteristics in an independent set of cases and comparators. Results: The development set for MPA consisted of 149 cases of MPA and 408 comparators. The validation set consisted of an additional 142 cases of MPA and 414 comparators. From 91 candidate items, regression analysis identified 10 items for MPA, 6 of which were retained. The final criteria and their weights were as follows: perinuclear antineutrophil cytoplasmic antibody (ANCA) or anti–myeloperoxidase‐ANCA positivity (+6), pauci‐immune glomerulonephritis (+3), lung fibrosis or interstitial lung disease (+3), sino‐nasal symptoms or signs (−3), cytoplasmic ANCA or anti–proteinase 3 ANCA positivity (−1), and eosinophil count ≥1 × 109/liter (−4). After excluding mimics of vasculitis, a patient with a diagnosis of small‐ or medium‐vessel vasculitis could be classified as having MPA with a cumulative score of ≥5 points. When these criteria were tested in the validation data set, the sensitivity was 91% (95% confidence interval [95% CI] 85–95%) and the specificity was 94% (95% CI 92–96%). Conclusion: The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for MPA are now validated for use in clinical research. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study.
- Author
-
Moiseev, Sergey, Kronbichler, Andreas, Makarov, Egor, Bulanov, Nikolay, Crnogorac, Matija, Direskeneli, Haner, Galesic, Kresimir, Gazel, Ummugulsum, Geetha, Duvuru, Guillevin, Loic, Hrušková, Zdenka, Little, Mark A, Ahmed, Adeel, McAdoo, Stephen P, Mohammad, Aladdin J, Moran, Sarah, Novikov, Pavel, Pusey, Charles D, Rahmattulla, Chinar, and Satrapová, Veronika
- Subjects
- *
THROMBOEMBOLISM risk factors , *SKIN diseases , *RESEARCH , *VEINS , *PULMONARY embolism , *CONFIDENCE intervals , *MULTIPLE regression analysis , *ANTINEUTROPHIL cytoplasmic antibodies , *MEDICAL cooperation , *TERTIARY care , *REGRESSION analysis , *RISK assessment , *KIDNEY diseases , *GRANULOMATOSIS with polyangiitis , *THROMBOEMBOLISM , *DESCRIPTIVE statistics , *STATISTICAL models , *ODDS ratio , *VASCULITIS , *MICROSCOPIC polyangiitis , *DISEASE complications - Abstract
Objective To investigate the occurrence of venous thromboembolic events (VTE) in a large cohort of patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) across the European Union, Turkey, Russia, UK and North America. Methods Patients with a definite diagnosis of AAV who were followed for at least 3 months and had sufficient documentation were included. Data on VTE, including either deep vein thrombosis or pulmonary embolism, were collected retrospectively from tertiary vasculitis centres. Univariate and multivariate regression models were used to estimate odds ratios (ORs) and 95% CIs. Results Over a median follow-up of 63 (interquartile range: 29, 101) months, VTE occurred in 278 (9.7%) of 2869 AAV patients with a similar frequency across different countries (from 6.3% to 13.7%), and AAV subtype [granulomatosis with polyangiitis: 9.8% (95% CI: 8.3, 11.6%); microscopic polyangiitis: 9.6% (95% CI: 7.9, 11.4%); and eosinophilic granulomatosis with polyangiitis: 9.8% (95% CI: 7.0, 13.3%)]. Most VTE (65.6%) were reported in the first-year post-diagnosis. Multiple factor logistic regression analysis adjusted for sex and age showed that skin (OR 1.71, 95% CI: 1.01, 2.92), pulmonary (OR 1.78, 95% CI: 1.04, 3.14) and kidney [eGFR 15–60 ml/min/1.73 m2, OR 2.86 (95% CI: 1.27, 6.47); eGFR <15 ml/min/1.73 m2, OR 6.71 (95% CI: 2.94, 15.33)] involvement were independent variables associated with a higher occurrence of VTE. Conclusion Two-thirds of VTE occurred during the initial phase of active disease. We confirmed previous findings from smaller studies that a decrease in kidney function, skin involvement and pulmonary disease are independently associated with VTE. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. Evaluation and validation of biomarkers in granulomatosis with polyangiitis and microscopic polyangiitis.
- Author
-
Kronbichler, Andreas, Kerschbaum, Julia, Gründlinger, Georg, Leierer, Johannes, Mayer, Gert, and Rudnicki, Michael
- Subjects
- *
GRANULOMATOSIS with polyangiitis diagnosis , *BIOMARKERS , *VASCULITIS , *ANTINEUTROPHIL cytoplasmic antibodies , *ENZYME-linked immunosorbent assay , *DIAGNOSIS ,MEDICAL literature reviews - Abstract
Background. Studies in anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) have revealed promising biomarkers. The aim of our study was to validate the most encouraging markers of granulomatosis with polyangiitis and microscopic polyangiitis identified by literature search and to create biomarker panels. Methods. A systematic literature review was performed and we identified 161 marker molecules that were ranked by their quantitative differential expression between active and inactive disease. Enzyme-linked immunosorbent assays were used to validate the results in a cross-sectional cohort of patients with renal involvement. Active vasculitis as assessed by the Birmingham Vasculitis Score version 3 (BVAS v3) was defined as BVAS v3 ≥1 and inactive disease as BVAS v3 = 0. Statistical analysis was performed with SPSS version 21 and the Salford Predictive Modeler 7.0 was used to generate a predictive biomarker panel. Results. The review indicated abundant expression of sC5bC9, C3a, C5a and monocyte chemotactic protein (MCP)-1 in urine, whereas granulocyte macrophage colony-stimulating factor, Creactive protein (CRP), soluble fms-like tyrosine kinase-1, interleukin-17A (IL-17A), C5a, hyaluronan, C3a and interleukin- 18 binding protein (IL-18BP) were identified to be highly diverse in active and inactive disease in blood samples. Our cross-sectional analysis revealed significant up-regulation of CRP, C5a, C3a, IL-18BP in blood and C5a and MCP-1 in urine samples during active AAV (all P < 0.05). Creation of a biomarker panel comprising CRP and urinary MCP-1 yielded a sensitivity and specificity of 76% (area under the curve 0.89). Conclusions. We identified promising biomarkers in a literature- based review that were in part corroborated as has been shown for CRP, C3a, C5a, IL-18BP in blood and MCP-1 and C5a in urine samples. Moreover, we propose a biomarker panel comprising CRP and urinary MCP-1 in patients with AAV and renal involvement. Further investigations to confirm our preliminary results are clearly warranted, including the reliability to predict disease relapses. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
9. Genetics of ANCA-associated vasculitis: role in pathogenesis, classification and management.
- Author
-
Trivioli, Giorgio, Marquez, Ana, Martorana, Davide, Tesi, Michelangelo, Kronbichler, Andreas, Lyons, Paul A., and Vaglio, Augusto
- Subjects
- *
CHURG-Strauss syndrome , *MICROSCOPIC polyangiitis , *VASCULITIS , *GENETICS , *ANTINEUTROPHIL cytoplasmic antibodies , *MUCOCUTANEOUS lymph node syndrome - Abstract
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) comprises granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA), that share features of pauci-immune small-vessel vasculitis and the positivity of ANCA targeting proteinase-3 (PR3-ANCA) or myeloperoxidase (MPO-ANCA). AAV syndromes are rare, complex diseases and their aetio-pathogenesis is mainly driven by the interaction between environmental and genetic factors. In patients with GPA and MPA, the genetic associations are stronger with ANCA specificity (PR3- versus MPO-ANCA) than with the clinical diagnosis, which, in keeping with the known clinical and prognostic differences between PR3-ANCA-positive and MPO-ANCA-positive patients, supports an ANCA-based re-classification of these disorders. EGPA is also made up of genetically distinct subsets, which can be stratified on ANCA-status (MPO ANCA-positive versus ANCA-negative); these subsets differ in clinical phenotype and possibly in their response to treatment. Interestingly, MPO-ANCA-positive patients with either MPA or EGPA have overlapping genetic determinants, thus strengthening the concept that this EGPA subset is closely related to the other AAV syndromes. The genetics of AAV provides us with essential information to understand its varied phenotype. This Review discusses the main findings of genetic association studies in AAV, their pathogenic implications and their potential effect on classification, management and prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.